Neo Soma Healthcare review

Two things here pull in opposite directions and both deserve saying. The good one is the semaglutide card, which prints the introductory price and the standing price in the same sentence. That is rare, and it removes the commonest way a reader on this site ends up surprised, which is finding out the real rate at the second charge rather than the first. The bad one is the cadence on the peptide lines. Sermorelin and NAD+ are both billed every four weeks, stated plainly, and four weeks comes round thirteen times in a year rather than twelve. The figure looks monthly and is not: the same number quoted every four weeks costs roughly nine per cent more over a year than it would per calendar month. Tirzepatide is the gap between the two. It is priced as an initial purchase with nothing beside it saying what the second one costs, so the molecule readers most often move up to is the one whose ongoing price is not printed. No milligram appears against any figure on the site.

Vs median

$24/mo above the $175 median across the 299 of 548 programs here that publish a plain monthly rate

Market

$59–$1,300/mo is the full published spread on this site

Structure

Standard plan, self-directed low dose

Consult

Included in the price

Dietitian

Not confirmed

Labs

Not required

Pricing

Check plan terms

Neo Soma Healthcare does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.

Two things on this site are worth a reader's attention and they pull in opposite directions. The good one is the semaglutide card, which prints the first-month price and the standing price in the same sentence. That is rare and it removes the single most common way a reader here ends up surprised, which is discovering the real rate at the second charge. The bad one is the cadence. The sermorelin and NAD+ lines are billed every four weeks rather than monthly, stated plainly on the card, and four weeks comes round thirteen times in a year rather than twelve. The number is the same but the year is not: a rate quoted every four weeks costs about 8.7% more annually than the identical figure quoted per calendar month. Tirzepatide is the gap. It is priced as an initial purchase and nothing on the card says what the second one costs, so the molecule this site's readers most often move to is the one whose ongoing price is not printed. No milligram appears against any figure.

Tirzepatide shows an initial purchase price with no standing rate printed beside it.

• The sermorelin and NAD+ lines bill every four weeks, which is thirteen charges a year.
• No dose is published against any figure on the site.

Neo Soma Healthcare is one of 548 low-dose GLP-1 programs compared on this site, and 299 of them publish a monthly rate you can read before signing up. The full list puts every published price in one place, with the companies that pay us listed first — something we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What microdosing GLP-1 costs
• Low dose vs full dose
• The true annual cost of a plan
• What a flat price costs at a low dose